Retatrutide Belly Fat: Does Reta Burn Visceral Fat Too?

Yes, retatrutide shrinks belly fat, including the deep visceral fat packed around your organs, but it doesn't pick the belly out. In the only study we found that scanned retatrutide belly fat, published in Nature Medicine in 2024, visceral fat fell by 16.1% to 48.3% over 48 weeks depending on the dose, and the fat under the skin of the belly fell by 13.2% to 43.5%. On placebo, visceral fat went up 2.5%. That study scanned 98 people. In Phase 3, waists on 12 mg shrank by an average of 9.5 inches in TRIUMPH-1, but as of October 2026 we found no Phase 3 result that reports a belly scan.

Belly fat comes in two layers. The one you can pinch sits under the skin. Visceral fat sits deeper, inside the abdominal wall around the liver and gut, and a tape measure can't tell the two apart. The NIH's heart institute (NHLBI) says fat around the waist rather than the hips raises the risk of heart disease and type 2 diabetes. As of October 2026, six Phase 3 trials have reported but no approved version of retatrutide exists, so every figure below comes from Lilly's own drug given in a trial.

What scans show about retatrutide belly fat

The fatty liver substudy of Lilly's Phase 2 obesity trial is the only place we found where belly fat on retatrutide was scanned directly. It used MRI to measure liver fat and the volume of both belly fat layers in 98 adults with fatty liver disease (MASLD), at the start, at week 24 and at week 48. The doses were 1, 4, 8 and 12 mg a week. The paper gives each belly fat layer as a range across the four doses.

Read down the week 48 column. No dose group lost more than 25.9% of its body weight, yet the biggest visceral fat drop was 48.3%. In percentage terms, visceral fat shrank by almost twice as much as body weight did.

Two cautions come with the table. The authors listed the belly fat measures as exploratory and compared them with placebo without adjusting for multiple tests. And by week 48 only 43.9% of the group had liver fat MRI data, because some people had stopped treatment or were scanned outside the visit window. The paper doesn't give the week 48 count for the belly fat measures, which came from the same MRI.

Does reta target visceral fat?

Not selectively, going by that study. Visceral fat and the fat under the skin fell by similar amounts at both time points, the deep layer a few points ahead. Both kept shrinking from week 24 to week 48.

Liver fat behaved differently. It dropped fast and early, close to its lowest point by about 20% weight loss, which lined up with roughly a 40% cut in each belly fat layer. After that the belly layers kept shrinking while liver fat had little left to lose.

The fatty liver page has the liver results. Nothing in the scans suggests retatrutide steers fat loss toward your stomach, though we found no study that measured hips, arms or face on their own.

If you've done well on tirzepatide and wonder whether switching would move a stubborn lower belly, no trial has compared the two drugs on belly fat. TRIUMPH-5, the first head-to-head against tirzepatide, measures body weight and waist size at week 80. ClinicalTrials.gov gives November 2026 as its estimated primary completion date, and Lilly hadn't reported it as of October 31, 2026. The one head-to-head result so far, TRANSCEND-T2D-2 against Ozempic 2 mg, reported weight (20.9% lost on 12 mg against 9.4%, efficacy estimand, 80 weeks) but no waist or scan figures. See retatrutide vs tirzepatide.

How much of the weight lost is fat?

The only whole-body scan data comes from a substudy of the Phase 2 type 2 diabetes trial, published in The Lancet Diabetes & Endocrinology in 2025. It used DXA, the low-dose X-ray scan that splits the body into fat, lean tissue and bone. Of 189 people enrolled, 103 finished with both scans.

In the main trial, the 12 mg group's weight fell 16.94% over the same 36 weeks. Fat mass fell by a bigger share than that, though the scanned subgroup isn't identical to the whole trial. The 8 mg groups losing more fat than 12 mg may be chance, since each substudy group had only about 30 people enrolled.

The 0.5 mg row bears on a question people on Reddit ask, whether a small "microdose" still burns fat. At 0.5 mg a week for 36 weeks, fat mass fell 4.9% against 4.5% on placebo, with no real difference. That's one group of 32 people with type 2 diabetes.

Does reta only burn fat? No. The study was funded by Lilly, and its authors wrote that the share of weight lost as lean tissue was similar to other obesity treatments, which means some muscle and other lean tissue goes too. The abstract doesn't give that lean figure, and we couldn't read the full paper. The retatrutide muscle loss page covers what scans show and what to do about it. The tirzepatide label says its drug lowers weight "with greater fat mass loss than lean mass loss", which is class evidence, not retatrutide data.

Does reta kill fat cells? We found no study that counted them. MRI and DXA measure how much fat there is, not how many cells hold it.

If you're "skinny fat", with a normal weight and not much muscle, there's no data for you. Both studies that scanned body fat enrolled people with overweight or obesity: a BMI of 25 to 50 in the Phase 2 diabetes trial and at least 27 in the Phase 2 obesity trial. Our read: a drug that takes some lean tissue along with the fat is a poor fit when the problem is too little muscle, and nobody has tested it in that group.

How does reta burn fat?

Mostly by making you eat less, as far as anyone can show. The tirzepatide label says that drug "decreases calorie intake" and that the effect is "likely mediated by affecting appetite". Retatrutide hits the same two receptors plus a third, and in TRIUMPH-2, 17.1% of people on 12 mg reported a smaller appetite as a side effect, against 4.5% on placebo.

The third receptor, glucagon, is where the "burns fat while you rest" claims come from. In Lilly's 2022 Cell Metabolism paper, the glucagon part of retatrutide raised energy use in obese lab animals on top of the drop in food intake. No published retatrutide study has tested that in people.

There is one human sign of the body switching to fat for fuel. In the fatty liver substudy, blood levels of beta-hydroxybutyrate, a marker of fat burning, rose 2 to 3 fold at 4 mg and above, and nobody developed ketoacidosis. The study couldn't separate glucagon's part from simply eating less.

Nobody has published a number for how much retatrutide raises metabolism in people. Lilly ran a Phase 1 study in 85 people with obesity on a calorie-restricted diet (NCT06313528). It compares retatrutide with placebo over about 16 weeks. The main measure is calorie intake at lunch and dinner, and 24-hour energy use and sleeping metabolic rate are secondary measures. ClinicalTrials.gov lists it as completed on August 26, 2025. When we checked on October 31, 2026, no results had been posted, so any extra-calories-per-day figure online didn't come from a published human study.

How many inches come off your waist?

TRIUMPH-1 randomized 2,339 people for 80 weeks, and waist size was one of its secondary results. The trial is now in the New England Journal of Medicine, but these figures are from Lilly's May 2026 topline, which assumes everyone stayed on treatment (the efficacy estimand). The average starting waist was 46.6 in (118.3 cm). The last two columns are our own arithmetic from Lilly's averages.

The ratio barely moves between doses: about a third of an inch of waist for every 1% of weight lost. For someone built like the average participant (248.5 lb, 46.6 in waist), a 10% loss works out to roughly 3.4 inches, and averages hide a wide spread. The weight loss calculator puts the trial averages against your own starting weight.

NHLBI puts the risk lines at more than 35 inches for women and more than 40 inches for men, measured with the tape just above your hipbones, read right after you breathe out. On 12 mg, the average participant finished at about 37.1 inches, under the men's line and still over the women's. That's a mixed average, since we found no waist results split by sex.

Does the ratio hold in other Phase 3 trials?

Roughly, yes. Lilly has given a highest-dose waist figure for four trials, and dividing by weight lost gives nearly the same answer each time.

Weight is the efficacy estimand in every row. We didn't find an estimand label on each waist figure, and TRANSCEND-T2D-1's waist number is Lilly's "up to" value, so its ratio is approximate.

Our read: a third of an inch per 1% of weight lost is a fair planning number, because it held across four trials and very different groups. A smaller starting waist than TRIUMPH-1's 46.6 in means fewer inches. For every trial's weight results, see retatrutide weight loss, and for how fast the weight comes off, the weight loss timeline.

What nobody has measured yet

Nearly all the belly fat evidence comes from two small Phase 2 substudies. As of October 2026, four pieces are missing.

• Phase 3 body scans. TRIUMPH-3 includes a DXA substudy of about 100 people measuring fat and lean mass, per the program's design paper in Diabetes, Obesity and Metabolism. Lilly's July 2026 topline didn't report it.
• Calorie burning in people. The 85-person study above is finished and has no posted results.
• Belly fat after stopping. The fatty liver study saw some weight come back at a check 4 weeks after the last dose, and we found no study that rescanned belly fat after that.
• Men against women. None of the belly fat or waist results in the papers and releases we read is split by sex.

All of these numbers come from Lilly's drug at known doses under trial supervision. Lilly's October 2026 FAQ warns that illicit products may have too much or too little active ingredient, or the wrong ingredient entirely. In a September 14, 2026 safety alert, Australia's TGA said a vial sold as retatrutide held no retatrutide when tested, only undeclared semaglutide at about 8 times the level in approved products. If you're weighing retatrutide for sale online, none of the scan results above tell you what's in a given vial.

When belly symptoms need a doctor

Stomach side effects are the most common complaint on retatrutide. In TRIUMPH-1, nausea affected 42.4% of people on 12 mg over 80 weeks, about 4 in 10, against 14.8% on placebo, and constipation affected 26.1% against 10.9%. The side effects hub breaks these down by dose.

If you go in, tell the doctor what you injected, the dose and where it came from. A mislabeled vial changes what they need to test for.